Acadia Pharmaceuticals (ACAD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.18
- EPS estimate
- $0.06
- EPS surprise
- +210.34%
- Revenue surprise
- +4.21%
- Revenue
- $308.0M
- Revenue estimate
- $295.5M
- Reported
- Aug 4, 2026
Acadia Pharmaceuticals reported Q2 2026 results on August 4, 2026. Earnings per share were $0.18, well above the $0.06 estimate, a 210.34% beat. Revenue of $308.0 million topped the $295.5 million consensus by 4.21%. Compared with Q2 2025, EPS rose from $0.16 and revenue grew about 16% from $264.6 million. Revenue was the highest quarterly figure in the table.
The table shows a shift from losses to profits. Acadia lost money in eight quarters between Q3 2021 and Q3 2023, including full-year losses of $1.34 per share in 2022 and $0.38 in 2023. Every quarter since Q4 2023 has been profitable. Annual EPS reached $1.36 in 2024 and $2.29 in 2025, while yearly revenue more than doubled from $517.3 million in 2022 to $1.07 billion in 2025. Q4 2025 EPS of $1.60 was the high in the table. The first half of 2026 totaled $0.20, against $0.27 a year earlier. Acadia beat EPS estimates in 14 of the last 20 quarters.
Q3 results came out between November 2 and November 8 in each of the past five years. That points to early November 2026 for the next report, which will show whether recent revenue growth continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.06 | $0.18 | +210.34% | $308.0M | SEC |
| Q1 2026 | May 6, 2026 | $0.05 | $0.02 | −60.40% | $268.1M | SEC |
| Q4 2025 | Feb 25, 2026 | $0.14 | $1.60 | +1067.88% | $284.0M | SEC |
| Q3 2025 | Nov 5, 2025 | $0.17 | $0.42 | +142.91% | $278.6M | SEC |
| Q2 2025 | Aug 6, 2025 | $0.14 | $0.16 | +15.86% | $264.6M | SEC |
| Q1 2025 | May 7, 2025 | $0.09 | $0.11 | +26.87% | $244.3M | SEC |
| Q4 2024 | Feb 26, 2025 | $0.22 | $0.86 | +298.70% | $259.6M | SEC |
| Q3 2024 | Nov 6, 2024 | $0.14 | $0.20 | +44.82% | $250.4M | SEC |
| Q2 2024 | Aug 6, 2024 | $0.18 | $0.20 | +12.55% | $242.0M | SEC |
| Q1 2024 | May 8, 2024 | $0.05 | $0.10 | +104.92% | $205.8M | SEC |
| Q4 2023 | Feb 27, 2024 | $0.29 | $0.28 | −3.08% | $231.0M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.45 | −$0.40 | +10.65% | $211.7M | SEC |
| Q2 2023 | Aug 2, 2023 | −$0.10 | $0.01 | +110.22% | $165.2M | SEC |
| Q1 2023 | May 8, 2023 | −$0.21 | −$0.27 | −25.87% | $118.5M | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.25 | −$0.26 | −5.22% | $136.5M | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.19 | −$0.17 | +12.46% | $130.7M | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.25 | −$0.21 | +15.25% | $134.6M | SEC |
| Q1 2022 | May 4, 2022 | −$0.62 | −$0.70 | −13.29% | $115.5M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.24 | −$0.27 | −13.64% | $130.8M | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.26 | −$0.09 | +65.32% | $131.6M | SEC |
Quarterly revenue
Frequently asked questions
When did Acadia Pharmaceuticals (ACAD) last report earnings?
Acadia Pharmaceuticals last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did ACAD beat earnings estimates?
Yes. Acadia Pharmaceuticals reported EPS of $0.18 for Q2 2026 against a $0.06 estimate — a 210.34% beat.
How much revenue did ACAD report last quarter?
Acadia Pharmaceuticals reported $308.0M in revenue for Q2 2026, against a consensus estimate of $295.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.